Farah Speer

Farah Speer is Senior Vice President, Communications and External Relations at AviadoBio.

Prior to this, Farah led communications for AveXis/Novartis Gene Therapies where she was responsible for establishing the company as a leader in gene therapy. While at Novartis, Farah led the launch of Zolgensma, a gene therapy approved by the US Food and Drug Administration (FDA) for children with spinal muscular atrophy (SMA), helping it to become the world’s most widely used gene therapy reaching over 2,000 patients and 43+ approvals globally.

Farah was also responsible for investor relations and internal communication to thousands of employees globally.

Farah’s experience prior to this was leading the North American healthcare practice at Golin, part of the Interpublic Group. In that role, Farah led the development of communications programs for global pharmaceutical, biotech and consumer healthcare companies on critical initiatives including corporate reputation, brand communications, consumer engagement and internal communications.

Farah graduated cum laude from the University of Notre Dame with a Master’s in Business Administration and has a Bachelor of Science in mass communication from Boston University’s College of Communication.